scholarly article | Q13442814 |
P356 | DOI | 10.1080/10428194.2018.1488253 |
P698 | PubMed publication ID | 30234404 |
P50 | author | Barbara Eichhorst | Q47158788 |
Stephan Stilgenbauer | Q47158807 | ||
Jasmin Bahlo | Q108428543 | ||
P2093 | author name string | Karl-Anton Kreuzer | |
Michael Hallek | |||
Marco Herling | |||
Georg Hopfinger | |||
Thorsten Zenz | |||
Alexandra Schrader | |||
Petra Mayer | |||
Anna-Maria Fink | |||
Natali Pflug | |||
Paula Cramer | |||
Anne Westermann | |||
Jan Dürig | |||
Till Seiler | |||
Sandra Robrecht | |||
Sebastian Oberbeck | |||
P433 | issue | 3 | |
P921 | main subject | lessons learned | Q1673259 |
phase II clinical trial | Q42824440 | ||
P304 | page(s) | 649-657 | |
P577 | publication date | 2018-09-20 | |
P1433 | published in | Leukemia & Lymphoma | Q6534493 |
P1476 | title | New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance | |
P478 | volume | 60 |
Search more.